Detection of human papillomavirus of high carcinogenic risk in women within the 1st stage of the oncosearch program in Yakutia
https://doi.org/10.25789/YMJ.2022.79.14
Abstract
The study was conducted as part of a pilot project at the Yakut Republican Oncological Dispensary titled ОНКОПОИСКСАХА.РФ (ONCOSEARCH), which is part of the national healthcare project. In 2021, 724 women from 5 uluses (villages) of the Republic of Sakha (Yaku-tia) and the city of Yakutsk took part in the study. The overall infection rate of high carcinogenic risk human papillomavirus (HCR HPV) among women in the Zhigansky Ulus was 10.6%, the Verkhoyansky Ulus – 4.7%, the Churapchinsky Ulus – 11%, the Namsky Ulus – 8.3%, the Srednekolymsky Ulus – 10.9%, and the city of Yakutsk – 5.5%. HCR HPV genotypes 16, 18 and 45 were identified as the most aggressive forms integrated into the human genome. In the article, we present the prevalence of HPV types by districts. We also highlight differences in in-fection among women of different age groups. The largest proportion of HCR HPV carriers falls on the age groups of 20-30 years (14.6%) and over 70 years (13.9%).
About the Authors
L. N. Afanasieva
M.K. Ammosov North-Eastern Federal University
Russian Federation
Russian Federation
Afanasieva Lena Nikolaevna – PhD of Medicine, Associate Professor
E. V. Filippov
Republic of Sakha (Yakutia) Yakut Republican Oncology Dispensar
Russian Federation
Russian Federation
Filippov Eduard Vasilyevich – PhD of Biology. biologist, Clinical and Diagnostic Laboratory of the State Budgetary Institution
G. V. Filippova
Republic of Sakha (Yakutia) Yakut Republican Oncology Dispensar;
Institute for Biological Problems of Cryolithozone Siberian Branch of Russian Academy of Sciences
Russian Federation
Russian Federation
Filippova Galina Valerievna – PhD of Biology, biologist, Pathological and Anatomical laboratory of the State Budgetary Institution of the Republic of Sakha (Yakutia) Yakut Republican Oncological Dispensary, Senior Researcher of the Institute for Biological Problems of Cryolithozone Siberian Branch of Russian Academy of Sciences
P. V. Nikiforov
Republic of Sakha (Yakutia) Yakut Republican Oncology Dispensar;
M.K. Ammosov North-Eastern Federal University
Russian Federation
Russian Federation
Nikiforov Petr Vladimirovich Deputy Chief Physician of the State Budgetary Institution of the Republic of Sakha (Yakutia) Yakut Republican Oncology Dispensary, associate professor of the Federal State Autonomous Educational Institution of Higher Education M.K. Ammosov North-Eastern Federal Universit
T. I. Nikolaeva
Republic of Sakha (Yakutia) Yakut Republican Oncology Dispensar;
M.K. Ammosov North-Eastern Federal University
Russian Federation
Russian Federation
Nikolaeva Tatyana Ivanovna –PhD of Medicine, Chief Physician of the State Budgetary Institution of the Republic of Sakha (Yakutia) Yakut Republican Oncology Dispensary, associate professor of the Federal State Autonomous Educational Institution of Higher Education M.K. Ammosov North-Eastern Federal University
References
1. Kaprin A.D. Malignant neoplasms in Russia in 2018 (morbidity and mortality) / A.D. Kaprin, V.V. Starinsky, G.M. Petrova. MNIOI them. Herzen PA.
2. WHO guidance note: comprehensive cervical cancer prevention and control: a healthier future for girls and women. 2013
3. The prevalence of papillomavirus infection in Russia / S.I. Rogovskaya, I.V. Mikheeva, O.Yu. Shipulina [et al.] // Epidemiology and vaccine prevention. 2012. No. 1 (62). - P. 25-33.
4. Buchanan TR, Graybill WS, Pierce JY. Morbidity and mortality of vul-var and vaginal cancers: Impact of 2-, 4-, and 9-valent HPV vaccines. Hum Vaccines Immunother. (2016) 12:1352–6. doi: 10.1080/21645515.2016.1147634.
5. Castle PE et al. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lan-cet Oncol. 2011 Sep;12(9): 880-90.
6. Debbie Saslow et.al. American Society for colposcopy and Cervical Pa-tology, and American So-ciety for Clinical Patology Screening Guidelines for the Prevention and Early Detection of Cer-vical Cancer. CA CANCER J CLIN 2012; 62:147-172.
7. De Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, et al. Global burden of cancers attributable to infections in 2008: a review and syn-thetic analysis. Lancet Oncol. (2012) 13:607–15. doi: 10.1016/S1470-2045(12)70137-7.
8. De Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. (2017) 141:664–70. doi: 10.1002/ijc.30716.
9. De Villiers, E.M., L. Gissmann, and H. zur Hausen.1981. Molecular cloning of viral DNA from human genital warts. J. Virol.40:932-935.
10. Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, et al. Global burden of human papillomavirus and related diseases. Vaccine. (2012) 30:F12–23. doi: 10.1016/j.vaccine.2012.07.055.
11. Gissmann, L., and H. zur Hausen.1980. Partial characterization of viral DNA from human genital warts (Condylomata acuminata). Int. J. Cancer 25:605-609.
12. Matlashewski G. /Anticancer Res. -1989.- №9.- p.1447-1456.
Review
For citations:
Afanasieva L.N., Filippov E.V., Filippova G.V., Nikiforov P.V., Nikolaeva T.I. Detection of human papillomavirus of high carcinogenic risk in women within the 1st stage of the oncosearch program in Yakutia. Yakut Medical Journal. 2022;(3):53-56. https://doi.org/10.25789/YMJ.2022.79.14
Views:
19
Email this article 